| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(4 years from now) | |
| US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(6 years from now) | |
| US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(4 years from now) | |
| US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(4 years from now) | |
| US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
| US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
| US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(4 years from now) | |
Tepmetko is owned by Emd Serono Inc.
Tepmetko contains Tepotinib Hydrochloride.
Tepmetko has a total of 8 drug patents out of which 0 drug patents have expired.
Tepmetko was authorised for market use on 03 February, 2021.
Tepmetko is available in tablet;oral dosage forms.
Tepmetko can be used as treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib, treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib.
Drug patent challenges can be filed against Tepmetko from 2025-02-03.
The generics of Tepmetko are possible to be released after 19 March, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 3, 2026 |
| Orphan Drug Exclusivity (ODE) | Feb 3, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 2025-02-03
Market Authorisation Date: 03 February, 2021
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
Dosage: TABLET;ORAL
TEPMETKO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic